Before a Request is Made

Before deciding whether this drug might be appropriate for your patient, please read our Investigator’s Brochure and Scientific Overview which detail RLF-100’s mechanism of action, indications, dosing and administration, and known adverse events.

Request Expanded Access for Aviptadil (RLF-100) for your Patients

Dear physician

Thank you for your interest in the Expanded Access Program for Aviptadil (RLF-100). This program was authorized by the FDA as an Intermediate-size Expanded Access Program.   Please note that this medication has not been approved by the FDA for any indication and is currently being studied in a clinical study of Intravenous Aviptadil for Critical COVID-19 with Respiratory Failure NCT04311697 (COVID-AIV).

Our Expanded Access Program is being managed by Clinigen.

Please note that NeuroRx and Clinigen are receiving a high volume of requests and we are working expeditiously to address these.

Due to the volume of requests, NeuroRx is unable to reply to voice mail messages on our system.

(Respiratory Failure is defined by the FDA as the requirement for mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen in excess of 20L/hr in order to maintain blood oxygen saturation.)
At this time, we are focused on institutions that expect to treat numerous patients under an Expanded Access Program.

Get information about the COVID-19 Expanded Access program